LUPUS NEPHRITIS

This study is testing whether adding an investigational drug called iptacopan to standard lupus nephritis treatment helps patients' kidneys recover better. It will involve about 240 adults with active kidney inflammation from lupus. Researchers will compare different doses of ipt…

This study is testing a new combination treatment for people with severe autoimmune diseases like lupus and scleroderma who haven't responded well to standard therapies. It involves giving specially modified immune cells (AD-PluReceptor-NK cells) along with a drug called tafasita…

This study is testing a single infusion of a genetically modified cell therapy called rapcabtagene autoleucel for adults with severe lupus or lupus kidney disease that hasn't responded to at least two standard treatments. The goal is to see if this one-time treatment can put the …

This early-stage study is testing the safety and early effectiveness of a new cell therapy called NKX019 for people with active lupus nephritis or primary membranous nephropathy, two serious autoimmune kidney diseases. Participants will receive a one-time treatment cycle involvin…

This study compares two ways of giving a medication called mycophenolate mofetil to children and young adults with lupus nephritis, a serious kidney complication of lupus. One group gets the standard dose based on body size, while the other gets a personalized dose adjusted based…

This study aims to understand how well the drug belimumab works in everyday medical practice to protect kidney function in adults with lupus nephritis. It will follow 300 participants for up to 5 years to see if the treatment helps them avoid severe kidney decline and the need fo…

This study is testing a new oral medication called IPG11406 for people with lupus nephritis, a serious kidney disease caused by lupus. The main goals are to find a safe dose and see if the drug shows early signs of helping control the disease by looking at kidney function and imm…

This early-stage study is testing a new treatment called UB-VV410 in adults whose lupus or lupus-related kidney disease is still active despite standard treatments. The main goals are to find the safest and most effective dose and to check for any side effects. Researchers will a…

This major Phase 3 trial is testing if a new drug combination can effectively treat lupus nephritis (a serious kidney complication of lupus) without needing high doses of oral steroids. The study will compare the standard steroid-based treatment against a new regimen using a drug…

This study is testing whether adding a new injectable drug called ianalumab to standard lupus nephritis treatment can better protect kidney function. About 462 adults with active lupus kidney disease will receive either ianalumab injections every 4 or 12 weeks or a placebo inject…

This study is testing an experimental cell therapy called CABA-201 for adults with active lupus. Doctors will collect a patient's own immune cells, modify them to target the harmful cells causing lupus, and infuse them back. The main goals are to see if this one-time treatment is…

This study is testing if using two newer drugs, belimumab and voclosporin, together works better to get lupus nephritis (kidney inflammation from lupus) into complete remission than what's been seen with either drug alone. It will involve about 30 adults with active kidney diseas…

This study is testing whether performing a second kidney biopsy one year after starting treatment helps people with lupus nephritis. About 206 adults with a first episode of lupus-related kidney inflammation will be randomly assigned to either get this follow-up biopsy or receive…

This study is testing an experimental one-time treatment called CC-97540 for people with active systemic lupus erythematosus (SLE), including lupus affecting the kidneys. The treatment involves collecting and genetically modifying a patient's own immune cells (CAR T-cells) to tar…

This study is testing an investigational drug called obinutuzumab in children and adolescents with a severe form of lupus that attacks the kidneys, known as lupus nephritis. The goal is to see if the drug can help control the kidney disease and allow patients to reduce their use …

This 2-year extension study follows patients with lupus nephritis, a serious kidney disease caused by lupus, who completed an earlier trial. It aims to see if patients who improved can safely stop taking the study drug (ianalumab) without their disease flaring up, and to continue…

This study is testing if an experimental drug called VIB4920 can help control kidney damage in people with active lupus nephritis. About 74 participants will receive either VIB4920 or a placebo (inactive substance) through an IV, along with standard medications, to see if it impr…

This early-stage study is testing a new treatment called CTX112 for adults with severe autoimmune diseases like lupus, scleroderma, and inflammatory muscle disease that haven't responded to standard therapies. The treatment uses genetically modified immune cells from healthy dono…

This study is a survey to monitor the safety of the drug LUPKYNIS in 400 patients with lupus nephritis (kidney inflammation from lupus) under real-world conditions. It will collect information on any side effects, how the drug is used, and its effectiveness in everyday practice. …